<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is associated with risk of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>), <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> and <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> itself is linked both to poor cognition and <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The ventricular N-terminal pro-brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (NT-proBNP) is a marker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>, suggesting potential as a marker for <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and/or <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>This was tested in the Edinburgh Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> Study (ET2DS) </plain></SENT>
<SENT sid="4" pm="."><plain>METHODOLOGY AND PRINCIPAL FINDINGS: Cross-sectional analysis of 1066 men and women aged 60-75 with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Results from seven neuropsychological tests were combined in a standardised general cognitive ability factor, 'g' </plain></SENT>
<SENT sid="6" pm="."><plain>A vocabulary-based test estimated pre-morbid cognitive ability </plain></SENT>
<SENT sid="7" pm="."><plain>The Hospital <z:hpo ids='HP_0000739'>Anxiety</z:hpo> and <z:hpo ids='HP_0000716'>Depression</z:hpo> Scale (HADS) assessed possible <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>After adjustment for age and sex, raised plasma NT-proBNP was weakly associated with lower 'g' and higher <z:hpo ids='HP_0000716'>depression</z:hpo> scores (ß -0.09, 95% CI -0.13 to -0.03, p = 0.004 and ß 0.08, 95% CI 0.04 to 0.12, p&lt;0.001, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Comparing extreme quintiles of NT-proBNP, subjects in the highest quintile were more likely to have reduced cognitive ability (within the lowest tertile of 'g') and 'possible' <z:hpo ids='HP_0000716'>depression</z:hpo> (HADS <z:hpo ids='HP_0000716'>depression</z:hpo> ≥8) (OR 1.80; 95% CI: 1.20, 2.70; p = 0.005 and OR 2.18; 95% CI: 1.28, 3.71; p = 0.004, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>Associations persisted when pre-morbid ability was adjusted for, but as expected were no longer statistically significant following the adjustment for <z:mp ids='MP_0002055'>diabetes</z:mp>-related and vascular co-variates (β -0.02, 95% CI -0.07 to 0.03, p&gt;0.05 for 'g'; β 0.03, 95% CI -0.02 to 0.07, p&gt;0.05 for <z:hpo ids='HP_0000716'>depression</z:hpo> scores) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Raised plasma NT-proBNP was weakly but statistically significantly associated with poorer cognitive function and <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The prospective phases of the ET2DS will help determine whether or not NT-proBNP can be considered a risk marker for subsequent <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and incident <z:hpo ids='HP_0000716'>depression</z:hpo> and whether it provides additional information over and above traditional risk factors for these conditions </plain></SENT>
</text></document>